Overview

Treatment of Hypersensitivity Syndrome (DRESS) With Tegeline® (Human Immunoglobulin)

Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Efficacy and tolerance of Tegeline® treatment in hypersensitivity syndrome. Immunological study of the T cell index phenotype and functionality in hypersensitivity syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Rouen